Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity

Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: An analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study

(2012) David C. Landy et al.   AMERICAN HEART JOURNAL

Cardiovascular Status of Childhood Cancer Survivors Exposed and Unexposed to Cardiotoxic Therapy

(2012) Steven E. Lipshultz et al.   JOURNAL OF CLINICAL ONCOLOGY

Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes

(2012) Steven E. Lipshultz et al.   JOURNAL OF CLINICAL ONCOLOGY

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2012) Edward H. Romond et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

(2012) Jersey Chen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors

(2011) C. Serrano et al.   ANNALS OF ONCOLOGY

Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer

(2011) Kathryn F. McGonigle et al.   CANCER

ABCC1polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia

(2011) Agnes F. Semsei et al.   CELL BIOLOGY INTERNATIONAL

A Novel Preclinical Strategy for Identifying Cardiotoxic Kinase Inhibitors and Mechanisms of Cardiotoxicity

(2011) Hui Cheng et al.   CIRCULATION RESEARCH

Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer

(2011) Luigi Tarantini et al.   JOURNAL OF CARDIAC FAILURE

Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab

(2011) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children

(2011) Henk Visscher et al.   JOURNAL OF CLINICAL ONCOLOGY

Proteomic insights into chronic anthracycline cardiotoxicity

(2011) Martin Štěrba et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes

(2011) Thomas Force et al.   NATURE REVIEWS DRUG DISCOVERY

Acute Mesenteric Infarction Associated with Atrial Fibrillation

(2011) Jia-Ming Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?

(2010) S. Verma et al.   ANNALS OF ONCOLOGY

Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues

(2010) Alberto Zambelli et al.   BREAST

Nox2 NADPH Oxidase Promotes Pathologic Cardiac Remodeling Associated with Doxorubicin Chemotherapy

(2010) Y. Zhao et al.   CANCER RESEARCH

Alpha-1-adrenergic receptors: Targets for agonist drugs to treat heart failure

(2010) Brian C. Jensen et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies

(2010) Geoffrey J. Yoon et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiotoxicity of anticancer treatments: what the cardiologist needs to know

(2010) Michael S. Ewer et al.   Nature Reviews Cardiology

Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer

(2010) F. Montemurro et al.   ONCOLOGIST

Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer

(2010) Howard R. Mellor et al.   TOXICOLOGICAL SCIENCES

Trastuzumab-Induced Cardiomyopathy: Not as Benign as it Looks? A Retrospective Study

(2009) Maya Guglin et al.   JOURNAL OF CARDIAC FAILURE

Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity

(2009) Masashi Yoshida et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21

(2009) D Rossi et al.   LEUKEMIA

Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood

(2009) Vladan Rajić et al.   LEUKEMIA & LYMPHOMA

Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy

(2009) Emanuel Raschi et al.   PHARMACOLOGY & THERAPEUTICS

Genetic polymorphisms in the carbonyl reductase 3 geneCBR3 and the NAD(P)H:quinone oxidoreductase 1 geneNQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer

(2008) Javier G. Blanco et al.   CANCER

Anthracycline Cardiotoxicity: From Bench to Bedside

(2008) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

Doxorubicin, Cardiac Risk Factors, and Cardiac Toxicity in Elderly Patients With Diffuse B-Cell Non-Hodgkin's Lymphoma

(2008) Dawn L. Hershman et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiac-Targeted Expression of Soluble Fas Attenuates Doxorubicin-Induced Cardiotoxicity in Mice

(2008) J. Niu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS